Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.
Carroll TM, Chadwick JA, Owen RP, White MJ, Kaplinsky J, Peneva I, Frangou A, Xie PF, Chang J, Roth A, Amess B, James SA, Rei M, Fuchs HS, McCann KJ, Omiyale AO, Jacobs BA, Lord SR, Norris-Bulpitt S, Dobbie ST, Griffiths L, Ramirez KA, Ricciardi T, Macri MJ, Ryan A, Venhaus RR, Van den Eynde BJ, Karydis I, Schuster-Böckler B, Middleton MR, Lu X; LUD2015-005 Project Team. Carroll TM, et al. Among authors: venhaus rr. Cancer Cell. 2023 Jul 10;41(7):1222-1241.e7. doi: 10.1016/j.ccell.2023.06.006. Cancer Cell. 2023. PMID: 37433281 Free article.
Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma.
Nayak L, Standifer N, Dietrich J, Clarke JL, Dunn GP, Lim M, Cloughesy T, Gan HK, Flagg E, George E, Gaffey S, Hayden J, Holcroft C, Wen PY, Macri M, Park AJ, Ricciardi T, Ryan A, Schwarzenberger P, Venhaus R, Reyes ML, Durham NM, Creasy T, Huang RY, Kaley T, Reardon DA. Nayak L, et al. Clin Cancer Res. 2022 Jun 13;28(12):2567-2578. doi: 10.1158/1078-0432.CCR-21-4064. Clin Cancer Res. 2022. PMID: 35395080 Free PMC article. Clinical Trial.
A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma.
Postow MA, Knox SJ, Goldman DA, Elhanati Y, Mavinkurve V, Wong P, Halpenny D, Reddy SK, Vado K, McCabe D, Ramirez KA, Macri M, Schwarzenberger P, Ricciardi T, Ryan A, Venhaus R, Momtaz P, Shoushtari AN, Callahan MK, Chapman PB, Wolchok JD, Subrahmanyam PB, Maecker HT, Panageas KS, Barker CA. Postow MA, et al. Clin Cancer Res. 2020 Jul 1;26(13):3193-3201. doi: 10.1158/1078-0432.CCR-19-3936. Epub 2020 Mar 23. Clin Cancer Res. 2020. PMID: 32205463 Free PMC article. Clinical Trial.
NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.
Chen JL, Dawoodji A, Tarlton A, Gnjatic S, Tajar A, Karydis I, Browning J, Pratap S, Verfaille C, Venhaus RR, Pan L, Altman DG, Cebon JS, Old LL, Nathan P, Ottensmeier C, Middleton M, Cerundolo V. Chen JL, et al. Among authors: venhaus rr. Int J Cancer. 2015 Mar 15;136(6):E590-601. doi: 10.1002/ijc.29118. Epub 2014 Aug 14. Int J Cancer. 2015. PMID: 25081390 Clinical Trial.
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
Slingluff CL, Zarour HM, Tawbi HA, Kirkwood JM, Postow MA, Friedlander P, Devoe CE, Gaughan EM, Mauldin IS, Olson WC, Smith KT, Macri MJ, Ricciardi T, Ryan A, Venhaus R, Wolchok JD. Slingluff CL, et al. Oncoimmunology. 2021 Mar 26;10(1):1898105. doi: 10.1080/2162402X.2021.1898105. Oncoimmunology. 2021. PMID: 33796406 Free PMC article. Clinical Trial.
A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers.
Gan HK, Parakh S, Lee FT, Tebbutt NC, Ameratunga M, Lee ST, O'Keefe GJ, Gong SJ, Vanrenen C, Caine J, Giovannetti M, Murone C, Scott FE, Guo N, Burvenich IJG, Paine C, Macri MJ, Kotsuma M, Senaldi G, Venhaus R, Scott AM. Gan HK, et al. Invest New Drugs. 2022 Aug;40(4):747-755. doi: 10.1007/s10637-022-01237-3. Epub 2022 Apr 11. Invest New Drugs. 2022. PMID: 35404015 Clinical Trial.
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.
Cebon JS, Gore M, Thompson JF, Davis ID, McArthur GA, Walpole E, Smithers M, Cerundolo V, Dunbar PR, MacGregor D, Fisher C, Millward M, Nathan P, Findlay MPN, Hersey P, Evans TRJ, Ottensmeier CH, Marsden J, Dalgleish AG, Corrie PG, Maria M, Brimble M, Williams G, Winkler S, Jackson HM, Endo-Munoz L, Tutuka CSA, Venhaus R, Old LJ, Haack D, Maraskovsky E, Behren A, Chen W. Cebon JS, et al. J Immunother Cancer. 2020 Apr;8(1):e000410. doi: 10.1136/jitc-2019-000410. J Immunother Cancer. 2020. PMID: 32317292 Free PMC article. Clinical Trial.
Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
Wada H, Isobe M, Kakimi K, Mizote Y, Eikawa S, Sato E, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Yamasaki M, Miyata H, Matsushita H, Udono H, Seto Y, Yamada K, Nishikawa H, Pan L, Venhaus R, Oka M, Doki Y, Nakayama E. Wada H, et al. J Immunother. 2014 Feb-Mar;37(2):84-92. doi: 10.1097/CJI.0000000000000017. J Immunother. 2014. PMID: 24509171 Clinical Trial.
Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.
Sabado RL, Pavlick A, Gnjatic S, Cruz CM, Vengco I, Hasan F, Spadaccia M, Darvishian F, Chiriboga L, Holman RM, Escalon J, Muren C, Escano C, Yepes E, Sharpe D, Vasilakos JP, Rolnitzsky L, Goldberg J, Mandeli J, Adams S, Jungbluth A, Pan L, Venhaus R, Ott PA, Bhardwaj N. Sabado RL, et al. Cancer Immunol Res. 2015 Mar;3(3):278-287. doi: 10.1158/2326-6066.CIR-14-0202. Epub 2015 Jan 29. Cancer Immunol Res. 2015. PMID: 25633712 Free PMC article. Clinical Trial.
19 results